Sudapyridine

Summary

Sudapyridine (CHEMBL5314931) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including tuberculosis and pulmonary tuberculosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 537.1 Da · C34H33ClN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314931
Name	Sudapyridine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	156777270
Molecular formula	C34H33ClN2O2
Molecular weight	537.1
InChIKey	MMUCHWPQRGEHDV-ZFEZZJPFSA-N

SMILES: CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=CC(=C4)C5=CC=C(C=C5)Cl)OC)O

IUPAC name: (1R,2S)-1-[5-(4-chlorophenyl)-2-methoxy-3-pyridinyl]-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol

Also known as: Sudapyridine, Wx-081, SUDAPYRIDINE

Parent form; salt/anhydrous children: CHEMBL5316189

Patent coverage: 1 distinct patent families (1 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
tuberculosis	3	MONDO:0018076	MONDO:0018076
pulmonary tuberculosis	2	MONDO:0006052	EFO:1000049

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05824871	PHASE3	RECRUITING	A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
NCT04608955	PHASE2	COMPLETED	Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
NCT06701110	PHASE1	RECRUITING	Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects
NCT06701136	PHASE1	NOT_YET_RECRUITING	Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults
NCT06117514	PHASE1	COMPLETED	Sudapyridine (WX-081) in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).